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Abstract
Background: A major impediment to tuberculosis control in Africa is the difficulty in diagnosing active tuberculosis (TB),
particularly in the context of HIV infection. We hypothesized that a unique host blood RNA transcriptional signature would
distinguish TB from other diseases (OD) in HIV-infected and -uninfected patients, and that this could be the basis of a simple
diagnostic test.
Methods and Findings: Adult case-control cohorts were established in South Africa and Malawi of HIV-infected or -
uninfected individuals consisting of 584 patients with either TB (confirmed by culture of Mycobacterium tuberculosis [M.TB]
from sputum or tissue sample in a patient under investigation for TB), OD (i.e., TB was considered in the differential
diagnosis but then excluded), or healthy individuals with latent TB infection (LTBI). Individuals were randomized into
training (80%) and test (20%) cohorts. Blood transcriptional profiles were assessed and minimal sets of significantly
differentially expressed transcripts distinguishing TB from LTBI and OD were identified in the training cohort. A 27 transcript
signature distinguished TB from LTBI and a 44 transcript signature distinguished TB from OD. To evaluate our signatures, we
used a novel computational method to calculate a disease risk score (DRS) for each patient. The classification based on this
score was first evaluated in the test cohort, and then validated in an independent publically available dataset
(GSE19491). In our test cohort, the DRS classified TB from LTBI (sensitivity 95%, 95% CI [87–100]; specificity 90%, 95% CI
[80–97]) and TB from OD (sensitivity 93%, 95% CI [83–100]; specificity 88%, 95% CI [74–97]). In the independent validation
cohort, TB patients were distinguished both from LTBI individuals (sensitivity 95%, 95% CI [85–100]; specificity 94%, 95% CI
[84–100]) and OD patients (sensitivity 100%, 95% CI [100–100]; specificity 96%, 95% CI [93–100]). Limitations of our study
include the use of only culture confirmed TB patients, and the potential that TB may have been misdiagnosed in a small
proportion of OD patients despite the extensive clinical investigation used to assign each patient to their diagnostic group.
Conclusions: In our study, blood transcriptional signatures distinguished TB from other conditions prevalent in HIV-infected
and -uninfected African adults. Our DRS, based on these signatures, could be developed as a test for TB suitable for use in
HIV endemic countries. Further evaluation of the performance of the signatures and DRS in prospective populations of
patients with symptoms consistent with TB will be needed to define their clinical value under operational conditions.
Please see later in the article for the Editors’ Summary.
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Introduction
There is an urgent need for improved tests to diagnose active
tuberculosis (TB), particularly in countries of sub-Saharan Africa
most affected by the TB/HIV pandemic. The diagnosis of TB was
problematic even before the emergence of HIV, as symptoms and
radiological features of TB overlap those of many other infectious
and non-infectious conditions. However in countries of sub-
Saharan Africa, where HIV prevalence amongst individuals
presenting with symptoms consistent with TB is over 50% [1],
the diagnostic difficulty is increased, as TB must be distinguished
from a wide range of opportunistic infections and HIV-associated
malignancies that present clinically with similar symptoms and
signs.
For over a century, diagnosis of TB has relied on clinical and
radiological features, sputum microscopy (with or without culture),
and tuberculin skin testing (TST). All of these have major
drawbacks, particularly in HIV co-infected individuals [2,3], in
whom radiological features are often atypical [4], cavitary lung
disease is less common [5,6], and results of sputum microscopy are
often negative [2,7]. Furthermore, culture facilities are largely
unavailable in many African hospitals [8]. As TST and interferon
gamma release assays (IGRAs) cannot discriminate TB from latent
TB infection (LTBI) [9], they are of limited diagnostic utility
amongst African adults where LTBI is highly prevalent in the
general population [10], and amongst inpatients with other
diagnoses. Molecular methods have improved detection of
Mycobacterium tuberculosis (M.TB) DNA in sputum [11], but the
sensitivity of this approach is lower in smear negative sputum
samples even if culture positive [12]. Consequently, high
proportions of patients with TB in sub-Saharan Africa remain
undiagnosed or are treated empirically without laboratory
confirmation. The need for improved diagnostic methods is
highlighted by post mortem studies showing TB to be a frequent
undiagnosed cause of death in Africa [13–15].
RNA expression analysis by microarray has emerged as a
powerful tool for understanding disease biology [16]. Many
diseases including cancer [17] and infectious diseases [18], as well
as TB [19–26], are associated with specific transcriptional profiles
in blood or tissue. Although previous studies in TB have suggested
that RNA expression might be used diagnostically to distinguish
TB from other conditions, these studies have excluded HIV-
infected participants, and have compared TB with other diseases
(OD) that are not representative of the spectrum seen in HIV-
infected and -uninfected patients presenting to African hospitals
with symptoms for which TB is included in the differential
diagnosis [19–26]. There is thus a need to identify biomarkers that
discriminate TB from OD prevalent in African populations, where
the burden of the HIV/TB pandemic is greatest.
In this two country prospective case-control study, we investi-
gated the hypothesis that host peripheral blood RNA expression
would distinguish TB from other conditions prevalent in African
populations in the context of endemic HIV infection, and explored
the use of a transcriptional signature as the basis for a diagnostic test.
Methods
Ethics Statement
The study was approved by the Human Research Ethics
Committee of the University of Cape Town, South Africa
(HREC012/2007), the National Health Sciences Research Com-
mittee, Malawi (NHSRC/447), and the Ethics Committee of the
London School of Hygiene and Tropical Medicine (5212). Written
information was provided by trained local health workers in local
languages and all patients provided written consent.
Study Sites
In order to enable generalization of our findings to African
countries with differing prevalence of malaria and other parasitic
infections, as well as other environmental exposures that might
affect transcriptional profiles, we chose highly contrasting study
sites (one urban, one rural) in two African countries with differing
co-endemic diseases:
Cape Town, South Africa. South Africa has one of the
highest TB incidence rates in Africa (981 per 100,000) [27], as well
as high rates of HIV infection (up to 41.8% prevalence in females
aged 25–35) [28]. Patients undergoing investigation for suspected
TB were recruited at GF Jooste Hospital Manenberg, Groote
Schuur Hospital, and at Khayelitsha site B clinics serving the
largely Xhosa population residing in the low income townships of
Cape Town. Malaria is not endemic in these urban populations.
Karonga district, Northern Malawi. The incidence of new
TB cases in Karonga district (180 per 100,000, Karonga
Prevention Study unpublished data, 2012) and the stable HIV
prevalence (10%–15% of females aged 25–29, Karonga Preven-
tion Study unpublished data, 2012) are lower in Karonga than in
Cape Town. Malaria and helminth infection are hyperendemic.
Patients were recruited at Karonga District hospital, which serves
a rural population living by the shores of Lake Malawi.
Diagnostic Process
To ensure accurate assignment of patients to definite TB and
OD groups, a rigorous diagnostic process was followed. All
patients underwent chest radiographs and serological testing for
HIV, along with cultures of blood, CSF, and urine, and biopsies
for histological examination including TB culture where clinically
indicated. Two sputum samples obtained after induction or
coughing were examined by standard microscopy for acid fast
bacilli (AFB) and cultured for TB using standard methods (i.e.,
solid media [South Africa and Malawi] and on liquid media
[South Africa only]) [29]. Patients were followed up 26 wk post
diagnosis to confirm that those with OD remained TB-free.
Individuals were either assigned to one of the diagnostic groups or
excluded once the results of investigations and follow-up were
available. Healthy LTBI controls were recruited by random
community selection (Malawi) and from HIV screening clinics
(South Africa) from the same catchment areas as patients with TB
(Figure 1). In vitro IGRA to substantiate LTBI was undertaken
using an in-house whole blood assay [30,31]. OD patients were
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recruited if they presented with symptoms that would mandate
investigation for TB as a differential diagnosis. After intensive
investigation, any case with an established alternative diagnosis to
TB, no microbiological evidence of TB, and an absence of TB
symptoms at the time of follow-up or with an observed
improvement of clinical symptoms on follow-up without TB
treatment, was recruited as an OD case. If TB could not be
reliably ruled out of the differential, the patient was excluded.
Patient Cohorts
Patient recruitment strategies, which differed at each site, were
embedded within health services administered by statutory
providers in order to best investigate on an ‘‘intention to test’’
basis.
Cape Town, South Africa. Recruitment in Cape Town
commenced 12th October 2007 and concluded 5th January 2010.
Subject to research staff availability, 96 sequential patients
presenting with at least one positive TB culture result were
recruited from an outpatient TB clinic in Khayelitsha site B until
49 HIV-infected and 47 HIV-uninfected persons were recruited
(Figure 2). In Cape Town, 36.7% (18/49) HIV-infected patients
with TB were smear-negative and 8.5% (4/47) HIV-uninfected
patients were smear-negative. Patients in the OD category were
recruited at GF Jooste and Groote Schuur hospitals in Cape
Town. Patients were assessed by a hospital clinician and enrolled
in the study if TB was considered in the differential diagnosis.
After intensive investigation as described above, patients were
assigned to the OD group if (1) an alternative diagnosis was
established; (2) no microbiological evidence of TB was found after
culture of sputum or other samples; and (3) an improvement of
clinical symptoms was observed on follow-up without TB
treatment (Figure 1). If a patient recruited to the OD group was
later found to be culture positive for M.TB, they were reclassified
appropriately. In total 138 HIV-infected and 80 HIV-uninfected
patients were recruited in the OD group, of which 70 HIV-
infected and 31 HIV-uninfected were excluded as TB diagnosis
could not be excluded (i.e., TB uncertain) (Figure 2).
Karonga district, Northern Malawi. Recruitment at Kar-
onga District Hospital commenced on 1st June 2007 and ceased
on the 30th November 2009. Patients attending the hospital were
assessed by a local clinician. If this clinician considered TB to be
within the differential diagnosis, patients were recruited by a study
staff member and investigated according to clinical and study
protocols as described above. Following the completion of in-
patient care, patients were followed up for at least 26 wk post
discharge to assess their progress including a verbal autopsy if the
patient had died. Individuals were categorized following the
completion of follow-up. Patients were assigned to the OD group if
Figure 1. Diagnostic process to identify TB cases, LTBI cases, and other diseases cases.
doi:10.1371/journal.pmed.1001538.g001
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(1) a firm alternative diagnosis was established; (2) there was no
microbiological evidence of TB; and (3) there was absence of
symptoms of TB at the time of follow-up or assignation of an
alternative cause of death on verbal autopsy (Figure 1). Individuals
who did not have TB and did not fulfill criteria for OD—e.g.,
failed to attend follow-up and with an unknown 6-mo outcome—
were categorized as ‘‘TB uncertain’’ (i.e., TB uncertain). During
the recruitment period 437 patients were recruited. Of these 254
had definite TB, 77 had a confirmed OD, and 106 were
categorized as TB cannot be excluded. The first 60 HIV-infected
and 59 HIV-uninfected patients with TB, along with all the OD
patients were included in the RNA expression study (Figure 2).
In Malawi, 13.3% (8/60) HIV-infected patients with TB were
smear-negative and 10.2% (6/59) HIV-uninfected patients were
smear-negative.
Oversight and Conduct of the Study
Patients were recruited by FZ and a team of research assistants
in Karonga, Malawi, and by TO and hospital staff in Cape Town,
South Africa. Assignment of patients to clinical groups was made
by consensus of two experienced clinicians at each site (indepen-
dent of those managing the patient clinically) after review of the
investigation results. Testing for HIV status was conducted after
appropriate counseling. Clinical data were anonymised and
patient samples identified only by study number. Statistical
analysis was conducted only after the RNA expression data and
the clinical databases had been locked and deposited for
independent verification.
Peripheral Blood RNA Expression by Microarray
Whole blood was collected at the time of recruitment (before or
within 24 h of commencing TB treatment in suspected patients) in
PAXgene blood RNA tubes (PreAnalytiX), frozen within 3 h of
collection, and later extracted using PAXgene blood RNA kits
(PreAnalytiX). RNA was shipped frozen to the Genome Institute
of Singapore for analysis on HumanHT-12 v.4 expression
Beadarrays (Illumina). Additional details of the microarray
method, quality control, and analysis are provided in Text S1.
Statistical Analysis
Expression data were analysed using ‘R’ Language and Environment
for Statistical Computing (R) 2.12.1 (Text S1). To identify transcript
signatures applicable across geographic locations and in patients
with differing HIV status, we combined HIV-infected and
-uninfected patient cohorts from South Africa and Malawi. The
recruited participants were randomly assigned to a training cohort
(80% of the participants) and a test cohort (20%) with no overlap,
using the ‘‘sample( )’’ function without replacement in ‘R’, which
obtains a subset of a given set [32]. For additional validation we
used the whole blood expression dataset from Berry et al. [25]
comparing TB with LTBI and other infectious diseases in an
African case-control study (accession GSE19491) (i.e., the ‘‘vali-
dation’’ dataset) (Text S1).
To detect transcripts that were differentially expressed between
patients with TB and comparator groups, a linear model was fitted
and moderated t-statistics calculated for each transcript with
correction for false discovery using Benjamini and Hochberg’s
method [33]. Significantly differentially expressed transcripts in
the training cohort with a |log2 fold change| (FC).0.5 were
subjected to variable selection using elastic net [34] (Text S1) in
order to identify the smallest number of transcripts distinguishing
TB from the comparator groups. These minimal transcript
selected sets for TB versus LTBI and TB versus OD (Tables S1T
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Table 2. Major clinical diagnoses in other diseases cohorts.
Other Diseases HIV Infected HIV Uninfected Total
SA Malawi SA Malawi
Pneumonia/LRTI/PJP 24 (35%) 19 (50%) 5 (10%) 13 (33%) 61 (31%)
Malignancy and other neoplasia other than Kaposi’s sarcomaa 2 (3%) 4 (11%) 17 (35%) 5 (13%) 28 (14%)
Pelvic inflammatory disease/UTI 4 (6%) 1 (3%) 15 (31%) 5 (13%) 25 (13%)
Bacterial, viral meningitis, or meningitis of uncertain origin 4 (6%) 4 (11%) 0 (0%) 6 (15%) 14 (7%)
Hepatobiliary disease 6 (9%) 0 (0%) 7 (14%) 0 (0%) 13 (7%)
Febrile syndromes of uncertain origin 1 (1%) 3 (8%) 1 (2%) 6 (15%) 11 (6)%
Kaposi’s sarcoma 9 (13%) 1 (3%) 0 (0%) 0 (0%) 10 (5%)
Cryptococcal meningitis 6 (9%) 4 (11%) 0 (0%) 0 (0%) 10 (5%)
Non TB pleural effusion/empyema 5 (7%) 0 (0%) 2 (4%) 0 (0%) 7 (4%)
Gastroenteritis 5 (7%) 0 (0%) 0 (0%) 0 (0%) 5 (3%)
Peritonitis 0 (0%) 1 (3%) 0 (0%) 3 (8%) 4 (2%)
Otherb 0 (0%) 1 (3)% 2 (4%) 1 (3%) 4 (2%)
Gastric ulcer or gastritis 2 (3%) 0 (0%) 0 (0%) 0 (0%) 2 (1%)
Total 68 38 49 39 194
aBronchial carcinoma (14), lymphoma (4), cervical carcinoma (1), ovarian carcinoma (1), mesothelioma (1), gastric carcinoma (1), metastatic carcinoma of unknown origin
(4), benign salivary tumour (1), dermatological tumour (1).
bHIV-related lymphadenopathy(1), Crohn9s disease (1), orchitis (1), pyomyositis (1).
LRTI, lower respiratory tract infection; PJP, Pneumocystis jirovecii pneumonia; SA, South Africa; UTI, urinary tract infection.
doi:10.1371/journal.pmed.1001538.t002
Figure 3. Heatmaps showing clustering of training and test cohorts using transcriptional signatures. Clustering of training (A/C) and
test (B/D) cohorts using transcripts identified by elastic net for TB versus LTBI (A/B) and TB versus OD (C/D) (training: nTB = 157 nLTBI = 128/nTB = 153
nOD = 140, test: nTB = 37 nLTBI = 39/nTB = 42 nOD = 34). Rows are transcripts (transcripts shown in red are up-regulated, those in green are down-
regulated) and columns are patients regardless of HIV status (purple, patients with TB; green, patients with LTBI; light blue, patients with OD).
doi:10.1371/journal.pmed.1001538.g003
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and S2) were assessed in the test cohort and further evaluated in
the validation dataset [25].
A Simplified Method for Identifying Individual Patient’s
Risk of Active TB
Current whole genome array-based technologies are not well
suited for use in resource poor settings as they are costly and
require sophisticated technology as well as bioinformatics
expertise. We therefore developed a method for translation of
multiple transcript RNA signatures into a disease risk score
(DRS), which could form the basis of a simple, low cost,
diagnostic test requiring basic laboratory facilities and minimal
bioinformatics analysis. For each individual, we calculated (on
normalized intensities) the DRS using the minimal transcript
selected sets for TB versus LTBI and TB versus OD. The score is
derived by adding the total intensity at up-regulated transcripts,
and subtracting the total intensity at all down-regulated
transcripts (Text S1). The threshold for the classification was
calculated as the weighted average of risk score within each class
(group of patients), with weights given as the inverse of the
standard deviation of the score within each class (Text S1). The
information that the DRS requires for classification (i.e., the
expression values of the transcripts of the signatures) can be
derived from the dataset itself, which allows its unbiased
application using expression data acquired using other array
platforms or non-array technologies. The sensitivity and speci-
ficity of the score in disease classification were evaluated on the
test cohort and validation dataset.
Accession Numbers
The data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus and are accessible through
GEO Series accession number GSE37250 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc =GSE37250).
Results
We recruited 311 adults to the South African cohort and 273 to
the Malawi cohort meeting the definitions for TB or OD, after
screening a total of 314 in South Africa and 437 patients in
Malawi (Figures 1 and 2; Table 1). After including samples from
LTBI controls that were recruited separately (98 and 77 patients in
South Africa and Malawi, respectively) and removing technical
failures (48 samples), 536 consecutive patient samples remained for
microarray analysis (Figure 2). The spectrum of infectious and
malignant diseases in the OD cohorts reflected the range of
conditions with similar clinical manifestations to TB at each site
(Table 2).
TB Specific RNA Signature That Is Independent of
Geographic Location and HIV Status
We performed quality control on the microarray data in
order to examine the effect of disease state on transcript
expression and to check for assignment errors. Inspection
revealed that the primary clustering was based on disease state
(TB, LTBI, OD) rather than geographical location or HIV
status (Figure S1). There was substantial correlation of TB
versus LTBI differential expression across different geographic
locations and HIV status, which was also seen for TB versus
OD (Figures S2 and S3). This indicates the presence of a robust
underlying signature of TB, independent of HIV status or
geographical location.
Identification and Validation of Minimal Transcript Sets
To find minimal transcript sets required to discriminate TB
from other groups, we applied the variable selection algorithm
elastic net [34] to the training cohort (Methods; Text S1). A 27
transcript model was identified for discriminating TB from LTBI
in the South Africa/Malawi training and test set (Figure 3A and
3B; Table S1), whilst a 44 transcript model was identified for
discriminating TB from OD (Figure 3C and 3D; Table S2). These
models were also applied to data from the South Africa validation
dataset [25], which, unlike our cohort, included only HIV-
uninfected participants (Figure S4).
Evaluation of a Simplified Disease Risk Score for TB
To evaluate the feasibility of using a simplified diagnostic test
based on our transcript sets for TB diagnosis in low resource
settings, we applied the DRS to our test cohort, which includes
patients that were not used to discover the signatures, and to the
South Africa validation dataset [25]. In our combined HIV-
infected and -uninfected test set, the 27 transcript DRS
discriminated TB from LTBI with sensitivity and specificity of
95%, 95% CI (87–100), and 90%, 95% CI (80–97), respectively,
whilst achieving perfect classification in the HIV-uninfected
cohorts and a slightly reduced accuracy in the HIV-infected
cohorts (Figures 4A, 5A, and 5B; Table 3). In the validation
dataset, the DRS achieved a sensitivity of 95%, 95% CI (85–100),
and a specificity of 94%, 95% CI (84–100) (Figure 4B; Table 3). As
for the discrimination between TB and OD, the 44 transcript DRS’s
sensitivity and specificity were 93%, 95% CI (83–100), and 88%,
95% CI (74–97), respectively, with consistent accuracy in the HIV-
infected and -uninfected test cohorts (Figures 4C, 5C, and 5D;
Table 3). In the validation dataset, the patients were classified with
100% sensitivity, 95% CI (100–100), and 96% specificity, 95% CI
(93–100) (Figure 4D; Table 3). Similar values for sensitivity and
specificity were obtained when the DRSwas evaluated in the training
dataset, demonstrating the robustness of our approach to avoid
overfitting (Table S5). In order to evaluate the classificatory power of
the DRS, we compared its performance with the regression model
derived from the elastic net based on the same signatures (Table S5).
We found that our DRS had similar accuracy in distinguishing TB
from LTBI and OD to the weighted regression model.
In order to assess the predictive value of our DRS in a cohort of
patients undergoing investigation for persistent symptoms such as
cough, fever, and weight loss, i.e., where TB was included in the
differential diagnosis, we used the prevalence of TB in our
prospective Malawi cohort (58%; 254 confirmed TB cases of 437
patients with suspected TB) to calculate the positive and negative
predictive value (PPV/NPV). The DRS for TB versus OD had a
PPV of 92%, 95% CI (84–99), and a NPV of 90%, 95% CI (80–
100) (Table S7). Using a 20% prevalence, which may be more
reflective of a general primary care setting in a high-burden
African country, NPV for TB versus OD is higher (98%, 95% CI
Figure 4. Classification using the disease risk score on the test cohort and validation dataset. Disease risk score and receiver operating
characteristic curves based on the TB/LTBI 27 transcript signature (A/B) and the TB/OD 44 transcript signature (C/D) applied to the South African (SA)/
Malawi HIV+/2 test cohort (A/C) (nTB = 37 nLTBI = 39/nTB = 42 nOD = 34) and independent validation dataset comprising South African patients (B/D)
(nTB = 20 nLTBI = 31 nOD = 82). Sensitivity, specificity are reported in Table 3. HIV+, HIV-infected; HIV2, HIV-uninfected. Classification cut-offs: (A) 138.98;
(B) 107.76; (C) 154.44; (D) 99.94.
doi:10.1371/journal.pmed.1001538.g004
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[96–100]), but PPV decreases (66%, 95% CI [46–87]), emphasiz-
ing the value of DRS as a rule-out test, with those patients with
positive DRS selected for further investigation (Table S7).
We also explored the effect of adjusting the threshold for the
DRS in assigning individual patients to TB or LTBI/OD. By
accepting a percentage of patients as ‘‘non-classifiable,’’ the
majority of patients under investigation are accurately assigned.
These ‘‘non-classifiable’’ patients could then be selected for more
detailed investigation (Figure S5).
As it would be advantageous to have a single signature that
distinguished TB from non-TB, we assessed the performance of a
signature in distinguishing TB from both TB and LTBI. A 53
transcript signature was identified (Table S3) that distinguished TB
from both LTBI and OD with sensitivity/specificity 91%/82%—a
lower performance than TB/LTBI and TB/OD signatures alone.
We also explored whether a smaller number of transcripts could
be used to distinguish TB from LTBI and from OD, which would
aid in manufacturing of a test (Text S1), resulting in a 21 and 29
transcript signature for distinguishing TB from LTBI and OD,
respectively. The sensitivity of the smaller models was 6%–10%
lower than the original models, while retaining the same specificity
for TB versus OD (Table S8).
In contrast to our approach, previous studies of RNA expression
as a diagnostic tool for TB have excluded HIV-infected patients,
and have used other disease controls that were not recruited
concurrently with TB cases or from the same population of
patients undergoing investigation for TB [19,21,22,24,25]. To
establish how these differences in biomarker study design might
affect performance of biomarker signatures, we compared the
performance of our 27 transcript TB/LTBI signature and our 44
transcript TB/OD signature with the performance of the
signatures of Berry et al. [25] for discrimination of TB versus
LTBI (393 transcripts) and TB versus OD (86 transcripts). While
the 393 TB/LTBI signature achieved a sensitivity of 88%, 95% CI
(80–94), and a specificity of 84%, 95% CI (76–92), on our TB
HIV-uninfected cohorts, the performance on the HIV-infected
group was 74%, 95% CI (65–82), and 80%, 95% CI (71–87),
respectively (Figure 6; Table 4). Furthermore, the Berry et al. TB/
OD 86 transcript signature had a lower performance on our
cohorts (sensitivity 71%, 95% CI (62–80), specificity 76%, 95% CI
(67–84), in HIV-uninfected; sensitivity 67%, 95% CI (58–75),
specificity 69%, 95% CI (59–78), in HIV-infected) (Figure 6;
Table 4). Thus our minimal transcript signatures and the DRS
method show better performance in distinguishing TB from LTBI
and OD (especially in the HIV-infected cohorts) than the much
larger number of transcripts identified by Berry et al. [25]. (Table 5)
Finally, we evaluated the performance of our signatures in the
smear-negative sub-group of patients with TB, the majority of
whom were HIV-infected (31 smear-negative TB patients with
definite negative smear status; seven TB HIV-uninfected and 24
TB HIV-infected). In the smear-negative patients the DRS showed
a sensitivity for detecting TB of 68%, 95% CI (52–84), when using
Figure 5. Application of the transcript signatures to the South African and Malawi test cohorts by HIV status. Disease risk score and
receiver operating characteristic curves based on the TB/LTBI 27 transcript signature (A/B) and the TB/OD 44 transcript signature (C/D) applied to the
HIV-uninfected (HIV2) (A/C) and HIV-infected (HIV+) (B/D) test cohort. Area under the curve, sensitivities, and specificities are reported in Table 3.
Classification cut-offs: (A) 131.37; (B) 142.84; (C) 151.10; (D) 142.84.
doi:10.1371/journal.pmed.1001538.g005
Table 3. Classification achieved using the disease risk score.
Measures South Africa/Malawi Test Cohort Validation Dataset
HIV+/2 (95% CI) HIV2 (95% CI) HIV+ (95% CI) HIV2 (95% CI)
TB versus LTBI (27 TB/LTBI transcript
signature)
Number of patients 76 38 38 51
Area under the curve 98% (95–100) 100% (100–100) 97% (95–100) 99% (97–100)
Sensitivity 95% (87–100) 100% (100–100) 94% (83–100) 95% (85–100)
Specificity 90% (80–97) 100% (100–100) 90% (75–100) 94% (84–100)
Likelihood ratio positive 9.23 (3.63–23.4) NA 9.44 (2.52–5.34) 14.73 (3.84–56.47)
Likelihood ratio negative 0.06 (0.02–0.23) 0 0.06 (0.01–0.42) 0.05 (0.01–0.36)
TB versus ODs (44 TB/OD transcript
signature)
Number of patients 76 37 39 102
Area under the curve 95% (89–99) 96% (89–100) 94% (83–100) 100%a (100–100)
Sensitivity 93% (83–100) 91% (77–100) 95% (85–100) 100% (100–100)
Specificity 88% (74–97) 93% (80–100) 84% (68–100) 96% (93–100)
Likelihood ratio positive 7.89 (3.13–19.89) 14.3 (2.15–95.12) 6.02 (2.1–17.08) 27.67 (9.11–84.03)
Likelihood ratio negative 0.08 (0.03–0.24) 0.05 (0.01–0.35) 0.06 (0.01–0.41) 0
The TB/LTBI 27 transcript signature and TB/OD 44 transcript signature were applied to the South African/Malawi HIV-uninfected (HIV2) and HIV-infected (HIV+) test
cohort and the independent validation dataset. Sensitivity and specificity calculated using the weighted threshold for classification. The actual numbers of patients that
were DRS negative and positive are shown in Table S4.
a99.94%.
HIV2; HIV-uninfected; HIV+; HIV-infected; NA; not applicable.
doi:10.1371/journal.pmed.1001538.t003
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Figure 6. Application of transcript signatures [25] to the combined South Africa and Malawi cohorts. Disease risk score and receiver
operating characteristic curves based on transcript signatures of Berry et al. [25] for TB versus LTBI (A/B/C) and TB versus OD (D/E/F) applied to the
combined training and test cohorts in HIV-uninfected (HIV2) and HIV-infected (HIV+) (A/D), HIV2 (B/E), and HIV+ (C/F) cohorts (Table 4 for
sensitivities, specificities, and area under the curve). Classification cut-offs: (A) 1,847.73; (B) 1,777.65; (C) 1,898.97; (D) 172.12; (E) 170.30; (F) 173.70.
doi:10.1371/journal.pmed.1001538.g006
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the TB versus LTBI signature and a sensitivity of 90%, 95% CI
(81–100), with the TB/OD signature, both of which are
comparable to results obtained in the larger HIV-infected cohort
of smear-positive and -negative patients. As we used the same
LTBI and OD patients from the test set, the specificity was
unchanged (90%, 95% CI (80–97), for TB versus LTBI and 88%,
95% CI (74–97), for TB versus OD) (Table S9).
Discussion
We have identified a host blood transcriptomic signature that
distinguishes TB from a wide range of OD prevalent in HIV-
infected and -uninfected African patients. We found that patients
with TB can be distinguished from LTBI with only 27 transcripts
and from OD with 44 transcripts. Our findings appear robust as
the results are reproducible in both HIV-infected and -uninfected
cohorts, in different geographic locations, and in an independent
TB patient dataset. The high sensitivity and specificity of the
signatures in distinguishing TB from OD, even in the HIV-
infected patients that have differing levels of T cell depletion and a
wide spectrum of opportunistic infections as well as HIV-related
complications, suggests that the signatures are promising biomark-
ers of TB. The relatively small number of transcripts in our
signatures may increase the potential for using transcriptional
profiling as a clinical diagnostic tool from a single peripheral blood
sample (i.e., using a multiplex assay [35,36]).
The major challenge for diagnosis of TB in Africa is how to
distinguish this disease from the range of other conditions that
show similar symptoms in countries where TB and HIV are co-
endemic. Previous TB biomarker studies have focused on
distinguishing patients with TB from healthy controls, or from
LTBI [21,22,24], or have used other disease controls that may not
represent the ‘‘real world’’ disease spectra from which TB should
be clinically differentiated [19,25]. Furthermore, these TB
biomarker studies have also excluded HIV co-infected patients
who are the group that most need new diagnostics. Our study
design should ensure that our signatures are applicable in TB/
HIV endemic countries as we recruited patients with TB
concurrently with patients with a range of conditions that present
with similar clinical features to TB, as well as recruiting both HIV-
infected and -uninfected individuals.
We have identified separate signatures for distinguishing TB/
OD and TB/LTBI, which only overlap in three transcripts. In
practice the clinical applications of these signatures might be
distinct as the TB/LTBI signature would be of value in contact
screening, where the concern is distinguishing active disease from
previous exposure in minimally symptomatic individuals. The
TB/OD signature would be of most value in evaluating
symptomatic patients presenting to medical services with symp-
toms of TB. We have also explored whether a single signature
might be used to distinguish TB from both LTBI and OD. The
combined signature showed lower performance to the separate
TB/LTBI and TB/OD signatures. Further exploration of the
operational performance of a combined signature or separate
signatures is needed to establish the best strategy.
Although our signatures and DRS distinguished the majority of
patients with TB from those with LTBI or OD, a proportion of
patients were not correctly classified. There is increasing
recognition that TB and LTBI may represent a dynamically
evolving continuum, particularly in HIV-infected patients and
thus failure to culture M.TB is not absolute proof that TB is not
present. Some false assignment by our current ‘‘gold standard’’ is
to be expected as noted by post mortem studies at which
undiagnosed TB is confirmed [14,15]. All patients in the OD
group presented with symptoms for which TB was included in the
differential diagnosis, and it is possible that TB may have been
misdiagnosed in a small proportion of OD patients despite the
extensive clinical investigation used to assign each patient to each
diagnostic group. Some improvement in sensitivity and specificity
of our DRS may also be achieved by weighting the signal from the
most discriminatory transcripts, and this could be explored in
subsequent refinements of the method.
A major concern in using transcriptional signatures as a clinical
diagnostic tool in resource poor settings is the complexity, as well
as cost, of the current methodologies. Our results have shown that
transcriptional signatures can be used to distinguish TB from OD
in an African setting. We explored the feasibility of a simplified
method for disease categorization that may facilitate development
of a diagnostic test based on our signatures. Our DRS provides a
new approach that enables the use of multi-transcript signatures
for individual disease risk assignment without the requirement for
complex analysis. Our method could be used to develop a simple
Table 4. Application of published signatures to the South Africa and Malawi cohorts.
Measures South African/Malawi Cohorts
HIV2/+ (95% CI) HIV2 (95% CI) HIV+ (95% CI)
TB versus LTBI (393 transcript signature)
Number of patients 361 180 181
Area under the curve 89% (86–92) 94% (91–97) 88% (82–92)
Sensitivity 82% (76–87) 88% (80–94) 74% (65–82)
Specificity 81% (75–87) 84% (76–92) 80% (71–87)
TB versus OD (86 transcript signature)
Number of patients 369 180 189
Area under the curve 76% (70–80) 78% (70–84) 75% (68–82)
Sensitivity 68% (61–73) 71% (62–80) 67% (58–75)
Specificity 70% (62–76) 76% (67–84) 69% (59–78)
Sensitivities, specificities, and area under curve based on transcript signatures of Berry et al. [25] for TB versus LTBI (393 transcripts), and TB versus OD (86 transcripts)
applied to the South African/Malawi HIV-uninfected (HIV2) and HIV-infected (HIV+) cohorts.
doi:10.1371/journal.pmed.1001538.t004
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test in which the transcripts comprising the diagnostic signature
(separated into those that are either up- or down-regulated in TB
relative to controls) are each measured using a suitable detection
system [35], and the combined signature used to identify each
patient’s risk of TB. For example, a simple test using the TB/OD
signature probes that show increased transcript expression in TB
relative to OD could be located in a single well or tube, and those
probes that show reduced transcript expression in TB located in a
second well or tube. Binding of RNA from a patient’s blood to
these probes could be detected as a combined signal from each
tube using one of the aforementioned detection systems. To allow
normalization, expression of up- or down-regulated transcripts in
an individual patient could be compared with that of housekeeping
genes, which do not show variation between healthy and disease
states. There are methods for rapid detection of multi-transcript
signatures including lateral flow reverse transcription (RT)-PCR
based systems, nano-pore technology [37], nano-particle enzyme
linked detection [38,39], and detection using nano-wires and
electrical impedance [40]. Some of these may be suitable for direct
analysis of multiple transcript signatures in blood and at a
relatively low cost.
While this study provides a proof of principle that relatively small
numbers of RNA transcripts can be used to discriminate active TB
from latent TB infection and OD in Africa, limitations remain that
need to be addressed in order to translate these results into a clinical
test. One such limitation is that our study has not assessed
performance of our DRS in patients treated for TB solely on the
basis of clinical suspicion, without any microbiological confirma-
tion. Amongst these ‘‘probable/possible’’ patients with TB, there is
no gold standard to evaluate any new biomarker. Exclusion of
probable/possible patients with TB may have produced better
estimates of sensitivity and specificity than would be achieved in a
prospective ‘‘all comers’’ study including the entire cohort of
patients in whom TB is included in the differential diagnosis. Thus,
further evaluation using a prospective population based study in
which the decision whether and when to initiate TB treatment is
evaluated against the new biomarker is required. Future studies will
also be required to refine the use of these biomarkers in a clinical
decision process either as an initial screening tool, or in conjunction
with more detailed culture based diagnostics.
From a clinical perspective a simple transcriptome-based test
that reliably diagnoses or excludes TB in the majority of patients
undergoing investigation for suspected TB, using a single blood
sample, would be of great value, allowing scarce hospital resources
to be focused on the small proportion of patients where the result
was indeterminate. The challenge for the academic research
community and for industry is to develop innovative methods to
translate multi-transcript signatures into simple, cheap tests for TB
suitable for use in African health facilities.
Supporting Information
Figure S1 Principal components analysis (PCA) of the
microarray samples. PCA plot based on all transcripts on all
samples after background adjustment and normalisation. A) PCA1
& PCA2 and B) PCA1 & PCA3. The sample highlighted
(categorised as active TB HIV+ from Malawi) was removed from
the analysis. Rings are levels of confidence (0.9 inner circle, 0.9999
outer circle).
(TIF)
Figure S2 Concordance of differential expression by
location of cohort and by HIV status for TB versus LTBI.
Concordance of differential expression by location of cohort (A/B)
and by HIV status (C/D) for the active TB versus latent
TB infection cohorts in South Africa and Malawi. Negative
logarithm of the corrected p-values in TB versus LTBI between
South Africa and Malawi for HIV-uninfected (HIV2) cohort (A)
and HIV-infected (HIV+) cohort (B); and between HIV2 and
HIV+ cohorts in South Africa (C) and in Malawi (D). There were
positive correlations between all comparisons. p = 0.05 is equiv-
alent to 2log p value = 1.3.
(TIF)
Figure S3 Concordance of differential expression by
location of cohort and by HIV status for TB versus OD.
Concordance of differential expression by location of cohort (A/B)
and by HIV status (C/D) for the active TB versus other disease
cohorts in South Africa and Malawi. Negative logarithm of the
corrected p-values in TB versus OD between South Africa and
Malawi for HIV-uninfected (HIV2) cohort (A) and HIV-infected
(HIV+) cohort (B); and between HIV2 and HIV+ cohorts in
South Africa (C) and in Malawi (D). There were positive
correlations between all comparisons. Note, the correlation
between South Africa/Malawi HIV2 cohorts is less than in
South Africa/Malawi HIV+ cohorts which may reflect the
different spectra of conditions in the ‘other disease’ cohorts.
p = 0.05 is equivalent to 2log p value = 1.3.
(TIF)
Figure S4 Heatmaps showing clustering of the indepen-
dent South African validation dataset based on the TB/
LTBI and TB/OD signatures. Clustering of TB versus LTBI
based on the TB/LTBI 27 transcript signature (A) and TB/OD 44
transcript signature (B) applied to the independent South African
validation datasets of Berry et al. [25]. Patients are represented as
columns (red are patients with TB, green are LTBI, blue are OD)
and individual transcripts are shown in rows (transcripts shown in
red are up-regulated and those in green are down-regulated).
(TIF)
Figure S5 Calculating the error rate of the classifiers.
The error rate of classification is presented in relation to the
percentage of unclassified samples. We present the error rate of
the classifier for the different groups using the 27 TB/LTBI
and 44 TB/OD transcript signatures in relation to the missing
rate we accept (HIV+ patients in red, HIV2 in blue and both
HIV+ & HIV2 in black; solid lines show the error rate for the
training cohorts while dotted lines show the error rate for the test
cohorts).
(TIF)
Table S1 The 27 transcript signature for distinguishing
TB from LTBI.
(DOC)
Table S2 The 44 transcript signature for distinguishing
TB from other diseases.
(DOC)
Table S3 The 53 transcript signature for detecting TB
from non-TB (i.e., LTBI and OD).
(DOC)
Table S4 Number of patients per group and calls of
DRS classification per group.
(DOC)
Table S5 Comparison of classification achieved using
elastic net derived linear classifier and disease risk
score for every pairwise comparison.
(DOC)
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Table S6 Classification achieved using the disease risk
score applied to the South African/Malawi HIV-unin-
fected (HIV2) and HIV-infected (HIV+) test cohort and
validation dataset with confidence intervals calculated
using the exact binomial method (Text S1).
(DOC)
Table S7 Positive and negative predictive values for the
classification achieved using the disease risk score
applied to the South African/Malawi HIV-uninfected
(HIV2) and HIV-infected (HIV+) test cohort and valida-
tion dataset.
(DOC)
Table S8 Performance of the smaller signatures when
applied to the South Africa/Malawi test set.
(DOC)
Table S9 Classification achieved using the disease risk
score applied to the South African/Malawi smear-
negative patients with TB and the controls from the test
cohort with confidence intervals calculated using the
bootstrapping and the exact binomial method.
(DOC)
Text S1 Appendix.
(DOC)
Text S2 STARD checklist.
(DOC)
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Editors’ Summary
Background. Tuberculosis (TB), caused by Mycobacterium
tuberculosis, is curable and preventable, but according to the
World Health Organization (WHO), in 2011, 8.7 million people
had symptoms of TB (usually a productive cough and fever)
and 1.4 million people—95% from low- and middle-income
countries—died from this infection. Worldwide, TB is also the
leading cause of death in people with HIV. For over a
century, diagnosis of TB has relied on clinical and radiological
features, sputum microscopy, and tuberculin skin testing but
all of these tests have major disadvantages, especially in
people who are also infected with HIV (HIV/TB co-infection)
in whom results are often atypical or falsely negative.
Furthermore, current tests cannot distinguish between
inactive (latent) and active TB infection. Therefore, there is
a need to identify biomarkers that can differentiate TB from
other diseases common to African populations, where the
burden of the HIV/TB pandemic is greatest.
Why Was This Study Done? Previous studies have
suggested that TB may be associated with specific transcrip-
tional profiles (identified by microarray analysis) in the blood
of the infected patient (host), which might make it possible
to differentiate TB from other conditions. However, these
studies have not included people co-infected with HIV and
have included in the differential diagnosis diseases that are
unrepresentative of the range of conditions common to
African patients. In this study of patients from Malawi and
South Africa, the researchers investigated whether blood
RNA expression could distinguish TB from other conditions
prevalent in African populations and form the basis of a
diagnostic test for TB (through a process using transcription
signatures).
What Did the Researchers Do and Find? The researchers
recruited patients with suspected TB attending one clinic in
Cape Town, South Africa between 2007 and 2010 and in one
hospital in Karonga district, Malawi between 2007 and 2009
(the training and test cohorts). Each patient underwent a
series of tests for TB (and had a blood test for HIV) and was
diagnosed as having TB if there was microbiological
evidence confirming the presence of Mycobacterium tuber-
culosis. At recruitment, each patient also had blood taken for
microarray analysis and following this assessment, the
researchers selected minimal transcript sets that distin-
guished TB from latent TB infection and TB from other
diseases, even in HIV-infected individuals. In order to help
form the basis of a simple, low cost, diagnostic test, the
researchers then developed a statistical method for the
translation of multiple transcript RNA signatures into a
disease risk score, which the researchers then checked using
a separate cohort of South African patients (the independent
validation cohort).
Using these methods, after screening 437 patients in Malawi
and 314 in South Africa, the researchers recruited 273
patients to the Malawi cohort and 311 adults to the South
African cohort (the training and test cohorts). Following
technical failures, 536 microarray samples were available for
analysis. The researchers identified a set of 27 transcripts that
could distinguish between TB and latent TB and a set of 44
transcripts that could distinguish TB from other diseases.
These multi-transcript signatures were then used to calculate
a single value disease risk score for every patient. In the test
cohorts, the disease risk score had a high sensitivity (95%)
and specificity (90%) for distinguishing TB from latent TB
infection (sensitivity is a measure of true positives, correctly
identified as such and specificity is a measure of true
negatives, correctly identified as such) and for distinguishing
TB from other diseases (sensitivity 93% and specificity 88%).
In the independent validation cohort, the researchers found
that patients with TB could be distinguished from patients
with latent TB infection (sensitivity 95% and specificity 94%)
and also from patients with other diseases (sensitivity 100%
and specificity 96%).
What Do These Findings Mean? These findings suggest
that a distinctive set of RNA transcriptional signatures
forming a disease risk score might provide the basis of a
diagnostic test that can distinguish active TB from latent TB
infection (27 signatures) and also from other diseases (44
signatures), such as pneumonia, that are prevalent in African
populations. There is a concern that using transcriptional
signatures as a clinical diagnostic tool in resource poor
settings might not be feasible because they are complex and
costly. The relatively small number of transcripts in the
signatures described here may increase the potential for
using this approach (transcriptional profiling) as a clinical
diagnostic tool using a single blood test. In order to make
most use of these findings, there is an urgent need for the
academic research community and for industry to develop
innovative methods to translate multi-transcript signatures
into simple, cheap tests for TB suitable for use in African
health facilities.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/
10.1371/journal.pmed.1001538.
N Wikipedia has definitions of tests for gene expression (note
that Wikipedia is a free online encyclopedia that anyone
can edit; available in several languages)
N The National Center for Biotechnology Information has a
fact sheet on microarray analysis
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
N The World Health Organization has up-to-date information
on TB
N The Stop TB partnership is working towards tuberculosis
elimination; patient stories about tuberculosis/HIV
coinfection are available
RNA Signature of Active TB in African Adults
PLOS Medicine | www.plosmedicine.org 17 October 2013 | Volume 10 | Issue 10 | e1001538
